Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem is a promising investment opportunity as its late-stage development in biopharmaceuticals, specifically in targeting signaling pathways in cancer cells, could lead to potentially significant long-term growth. With a strong pipeline and recent earnings report showing a revenue miss due to seasonality and early stage patients, the company is focused on ramping up commercial efforts and has a healthy amount of cash for continued research and development. The upcoming data releases for VS-7375 and RAMP 205 could offset any short-term turbulence and highlight the potential for substantial peak sales, while partnerships for commercialization and the potential for combination regimens further support the company's growth potential.

Bears say

Verastem is heavily dependent on the success of their two main programs, RAMP 205 and GenFleet, which are still in early stages of development. While initial data for both programs showed promising response rates, it is unclear if these results can be replicated in larger patient populations, and management's ORR goal of ≥50% may be overly ambitious. Furthermore, the company has yet to report any significant revenue and is burning through its cash reserves, making it a high-risk investment.

Verastem (VSTM) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.